The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity

Cytochrome P450s (CYP) play a pivotal role in the metabolism of drugs and xenobiotics, and have been intensively studied over many years. Much of the work carried out on the role of hepatic cytochrome P450s in drug metabolism and disposition has been done in vitro, and has yielded vital information...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Toxicology letters 2006-03, Vol.162 (1), p.111-117
Hauptverfasser: Henderson, Colin J., Pass, Georgia J., Wolf, C. Roland
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 117
container_issue 1
container_start_page 111
container_title Toxicology letters
container_volume 162
creator Henderson, Colin J.
Pass, Georgia J.
Wolf, C. Roland
description Cytochrome P450s (CYP) play a pivotal role in the metabolism of drugs and xenobiotics, and have been intensively studied over many years. Much of the work carried out on the role of hepatic cytochrome P450s in drug metabolism and disposition has been done in vitro, and has yielded vital information on P450 regulation and function. However, additional factors such as route of administration, absorption, drug transporters, renal clearance and extra-hepatic P450s, make it difficult to extrapolate from in vitro data to in vivo pharmacokinetics. A number of cytochrome P450s knockout mice have been generated, although many have been of limited usefulness due to either embryonic/perinatal lethality, or the functional redundancy inevitably found in a large family of isoenzymes. We have developed a mouse line (HRN) in which cytochrome P450 oxidoreductase (POR), the unique electron donor to cytochrome P450s is deleted specifically in the liver, resulting in the loss of essentially all hepatic P450 function. The HRN mouse, although having disturbances in lipid and bile acid homeostasis develops and breeds normally. We have used the HRN mouse as a model to establish the role of hepatic versus extra-hepatic metabolism in drug metabolism and disposition, and also to investigate the relationship between drug toxicokinetics and therapeutic effect, initially with the chemotherapeutic prodrug cyclophosphamide (CPA).
doi_str_mv 10.1016/j.toxlet.2005.10.016
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17479825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378427405003565</els_id><sourcerecordid>17479825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-f9605c18752a7aeec08726a880512b1bb742d715fe9acda5d3a32229e364d5ae3</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMoWh__QCQrd1PznMxsBBFfIOhC1yFN7tCUmUlNMmL_vSktuHOThC_nnnvvQeiSkjkltL5ZzXP46SHPGSGyoHmBB2hGG9VWnNbtIZoRrppKMCVO0GlKK0JILWp5jE5ozQVvGJ8h97EEvIS1yd5iu8nBLmMYAL8LSXAEN9lsEuBx6ns8hKk8TcIG5xD6cmDvYMy-2xSUJmshpW7qsTWj885kwNvfvDlHR53pE1zs7zP0-fjwcf9cvb49vdzfvVaWtzRXXVsTacsCkhllACxpFKtN0xBJ2YIuFkowp6jsoDXWGem44YyxFngtnDTAz9D1zncdw9cEKevBJwt9b0Yos2uqhGobJotQ7IQ2hpQidHod_WDiRlOit-nqld6lq7fpbmmBpexq7z8tBnB_Rfs4i-B2J4Cy5beHqJP1MFpwPoLN2gX_f4dfKpWN-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17479825</pqid></control><display><type>article</type><title>The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Henderson, Colin J. ; Pass, Georgia J. ; Wolf, C. Roland</creator><creatorcontrib>Henderson, Colin J. ; Pass, Georgia J. ; Wolf, C. Roland</creatorcontrib><description>Cytochrome P450s (CYP) play a pivotal role in the metabolism of drugs and xenobiotics, and have been intensively studied over many years. Much of the work carried out on the role of hepatic cytochrome P450s in drug metabolism and disposition has been done in vitro, and has yielded vital information on P450 regulation and function. However, additional factors such as route of administration, absorption, drug transporters, renal clearance and extra-hepatic P450s, make it difficult to extrapolate from in vitro data to in vivo pharmacokinetics. A number of cytochrome P450s knockout mice have been generated, although many have been of limited usefulness due to either embryonic/perinatal lethality, or the functional redundancy inevitably found in a large family of isoenzymes. We have developed a mouse line (HRN) in which cytochrome P450 oxidoreductase (POR), the unique electron donor to cytochrome P450s is deleted specifically in the liver, resulting in the loss of essentially all hepatic P450 function. The HRN mouse, although having disturbances in lipid and bile acid homeostasis develops and breeds normally. We have used the HRN mouse as a model to establish the role of hepatic versus extra-hepatic metabolism in drug metabolism and disposition, and also to investigate the relationship between drug toxicokinetics and therapeutic effect, initially with the chemotherapeutic prodrug cyclophosphamide (CPA).</description><identifier>ISSN: 0378-4274</identifier><identifier>EISSN: 1879-3169</identifier><identifier>DOI: 10.1016/j.toxlet.2005.10.016</identifier><identifier>PMID: 16343823</identifier><language>eng</language><publisher>Netherlands: Elsevier Ireland Ltd</publisher><subject>Animals ; Antineoplastic Agents - metabolism ; Liver - enzymology ; Male ; Mice ; Mice, Knockout ; Models, Animal ; NADPH-Ferrihemoprotein Reductase - deficiency ; NADPH-Ferrihemoprotein Reductase - genetics ; P450 ; Pharmacokinetics ; Reductase ; Toxicokinetics ; Transgenic</subject><ispartof>Toxicology letters, 2006-03, Vol.162 (1), p.111-117</ispartof><rights>2005 Elsevier Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-f9605c18752a7aeec08726a880512b1bb742d715fe9acda5d3a32229e364d5ae3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.toxlet.2005.10.016$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16343823$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Henderson, Colin J.</creatorcontrib><creatorcontrib>Pass, Georgia J.</creatorcontrib><creatorcontrib>Wolf, C. Roland</creatorcontrib><title>The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity</title><title>Toxicology letters</title><addtitle>Toxicol Lett</addtitle><description>Cytochrome P450s (CYP) play a pivotal role in the metabolism of drugs and xenobiotics, and have been intensively studied over many years. Much of the work carried out on the role of hepatic cytochrome P450s in drug metabolism and disposition has been done in vitro, and has yielded vital information on P450 regulation and function. However, additional factors such as route of administration, absorption, drug transporters, renal clearance and extra-hepatic P450s, make it difficult to extrapolate from in vitro data to in vivo pharmacokinetics. A number of cytochrome P450s knockout mice have been generated, although many have been of limited usefulness due to either embryonic/perinatal lethality, or the functional redundancy inevitably found in a large family of isoenzymes. We have developed a mouse line (HRN) in which cytochrome P450 oxidoreductase (POR), the unique electron donor to cytochrome P450s is deleted specifically in the liver, resulting in the loss of essentially all hepatic P450 function. The HRN mouse, although having disturbances in lipid and bile acid homeostasis develops and breeds normally. We have used the HRN mouse as a model to establish the role of hepatic versus extra-hepatic metabolism in drug metabolism and disposition, and also to investigate the relationship between drug toxicokinetics and therapeutic effect, initially with the chemotherapeutic prodrug cyclophosphamide (CPA).</description><subject>Animals</subject><subject>Antineoplastic Agents - metabolism</subject><subject>Liver - enzymology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Models, Animal</subject><subject>NADPH-Ferrihemoprotein Reductase - deficiency</subject><subject>NADPH-Ferrihemoprotein Reductase - genetics</subject><subject>P450</subject><subject>Pharmacokinetics</subject><subject>Reductase</subject><subject>Toxicokinetics</subject><subject>Transgenic</subject><issn>0378-4274</issn><issn>1879-3169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLAzEUhYMoWh__QCQrd1PznMxsBBFfIOhC1yFN7tCUmUlNMmL_vSktuHOThC_nnnvvQeiSkjkltL5ZzXP46SHPGSGyoHmBB2hGG9VWnNbtIZoRrppKMCVO0GlKK0JILWp5jE5ozQVvGJ8h97EEvIS1yd5iu8nBLmMYAL8LSXAEN9lsEuBx6ns8hKk8TcIG5xD6cmDvYMy-2xSUJmshpW7qsTWj885kwNvfvDlHR53pE1zs7zP0-fjwcf9cvb49vdzfvVaWtzRXXVsTacsCkhllACxpFKtN0xBJ2YIuFkowp6jsoDXWGem44YyxFngtnDTAz9D1zncdw9cEKevBJwt9b0Yos2uqhGobJotQ7IQ2hpQidHod_WDiRlOit-nqld6lq7fpbmmBpexq7z8tBnB_Rfs4i-B2J4Cy5beHqJP1MFpwPoLN2gX_f4dfKpWN-Q</recordid><startdate>20060315</startdate><enddate>20060315</enddate><creator>Henderson, Colin J.</creator><creator>Pass, Georgia J.</creator><creator>Wolf, C. Roland</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20060315</creationdate><title>The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity</title><author>Henderson, Colin J. ; Pass, Georgia J. ; Wolf, C. Roland</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-f9605c18752a7aeec08726a880512b1bb742d715fe9acda5d3a32229e364d5ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - metabolism</topic><topic>Liver - enzymology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Models, Animal</topic><topic>NADPH-Ferrihemoprotein Reductase - deficiency</topic><topic>NADPH-Ferrihemoprotein Reductase - genetics</topic><topic>P450</topic><topic>Pharmacokinetics</topic><topic>Reductase</topic><topic>Toxicokinetics</topic><topic>Transgenic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henderson, Colin J.</creatorcontrib><creatorcontrib>Pass, Georgia J.</creatorcontrib><creatorcontrib>Wolf, C. Roland</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Toxicology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henderson, Colin J.</au><au>Pass, Georgia J.</au><au>Wolf, C. Roland</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity</atitle><jtitle>Toxicology letters</jtitle><addtitle>Toxicol Lett</addtitle><date>2006-03-15</date><risdate>2006</risdate><volume>162</volume><issue>1</issue><spage>111</spage><epage>117</epage><pages>111-117</pages><issn>0378-4274</issn><eissn>1879-3169</eissn><abstract>Cytochrome P450s (CYP) play a pivotal role in the metabolism of drugs and xenobiotics, and have been intensively studied over many years. Much of the work carried out on the role of hepatic cytochrome P450s in drug metabolism and disposition has been done in vitro, and has yielded vital information on P450 regulation and function. However, additional factors such as route of administration, absorption, drug transporters, renal clearance and extra-hepatic P450s, make it difficult to extrapolate from in vitro data to in vivo pharmacokinetics. A number of cytochrome P450s knockout mice have been generated, although many have been of limited usefulness due to either embryonic/perinatal lethality, or the functional redundancy inevitably found in a large family of isoenzymes. We have developed a mouse line (HRN) in which cytochrome P450 oxidoreductase (POR), the unique electron donor to cytochrome P450s is deleted specifically in the liver, resulting in the loss of essentially all hepatic P450 function. The HRN mouse, although having disturbances in lipid and bile acid homeostasis develops and breeds normally. We have used the HRN mouse as a model to establish the role of hepatic versus extra-hepatic metabolism in drug metabolism and disposition, and also to investigate the relationship between drug toxicokinetics and therapeutic effect, initially with the chemotherapeutic prodrug cyclophosphamide (CPA).</abstract><cop>Netherlands</cop><pub>Elsevier Ireland Ltd</pub><pmid>16343823</pmid><doi>10.1016/j.toxlet.2005.10.016</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-4274
ispartof Toxicology letters, 2006-03, Vol.162 (1), p.111-117
issn 0378-4274
1879-3169
language eng
recordid cdi_proquest_miscellaneous_17479825
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Antineoplastic Agents - metabolism
Liver - enzymology
Male
Mice
Mice, Knockout
Models, Animal
NADPH-Ferrihemoprotein Reductase - deficiency
NADPH-Ferrihemoprotein Reductase - genetics
P450
Pharmacokinetics
Reductase
Toxicokinetics
Transgenic
title The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T12%3A04%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20hepatic%20cytochrome%20P450%20reductase%20null%20mouse%20as%20a%20tool%20to%20identify%20a%20successful%20candidate%20entity&rft.jtitle=Toxicology%20letters&rft.au=Henderson,%20Colin%20J.&rft.date=2006-03-15&rft.volume=162&rft.issue=1&rft.spage=111&rft.epage=117&rft.pages=111-117&rft.issn=0378-4274&rft.eissn=1879-3169&rft_id=info:doi/10.1016/j.toxlet.2005.10.016&rft_dat=%3Cproquest_cross%3E17479825%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17479825&rft_id=info:pmid/16343823&rft_els_id=S0378427405003565&rfr_iscdi=true